Evaluation of Escherichia coli membrane preparations of canine CYP1A1, 2B11, 2C21, 2C41, 2D15, 3A12, and 3A26 with coexpressed canine cytochrome P450 reductase

Drug Metabolism and Disposition

Volumn 37, Issue 3, 2009, Pages 457-461

  Locuson, Charles W ^a,e   Ethell, Brian T ^b   Voice, Michael ^c   Lee, David ^d   Feenstra, Kenneth L ^a  

^a ZOETIS   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c Dundee DD2 1NH   (United Kingdom)

^d Advantagen Ltd   (United Kingdom)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUFURALOL; CYTOCHROME P450 1A1; CYTOCHROME P450 2B11; CYTOCHROME P450 2C21; CYTOCHROME P450 2C41; CYTOCHROME P450 2D15; CYTOCHROME P450 3A12; CYTOCHROME P450 3A26; CYTOCHROME P450 ISOENZYME; CYTOCHROME P450 REDUCTASE; DICLOFENAC; MIDAZOLAM; PHENACETIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BACTERIAL MEMBRANE; CATALYSIS; CONTROLLED STUDY; DEMETHYLATION; DOG; DRUG HYDROXYLATION; ESCHERICHIA COLI; LIVER MICROSOME; LIVER MICROSOME METABOLISM; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BASE SEQUENCE; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; DNA, COMPLEMENTARY; DOGS; ESCHERICHIA COLI; MEMBRANE PROTEINS; NADPH-FERRIHEMOPROTEIN REDUCTASE; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

BACTERIA (MICROORGANISMS); CANIS FAMILIARIS; ESCHERICHIA COLI;

EID: 61449228435     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.025312     Document Type: Article

References (22)

1. Aidasani D, Zaya MJ, Malpas PB, and Locuson CW (2008) In vitro drug-drug interaction screens for canine veterinary medicines: evaluation of cytochrome P450 reversible inhibition. Drug Metab Dispos 36.1512-1518.
2. Barnes HJ, Arlotto MP, and Waterman MR (1991) Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli. Proc Natl Acad Sci USA 88.5597-5601.
3. Blake JA, Pritchard M, Ding S, Smith GC, Burchell B, Wolf CR, and Friedberg T (1996) Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coli. FEBS Lett 397:210-214.
4. Carr B, Norcross R, Fang Y, Lu P, Rodrigues AD, Shou M, Rushmore T, and Booth-Genthe C (2006) Characterization of the rhesus monkey CYP3A64 enzyme: species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes. Drug Metab Dispos 34.1703-1712.
5. Crespi CL and Stresser DM (2000) Fluorometric screening for metabolism-based drug-drug interactions. J Pharmacol Toxicol Methods 44:325-331.
6. Eguchi K, Nishibe Y, Baba T, and Ohno K (1996) Quantitation of cytochrome P450 enzymes (CYP1A1/2, 2B11, 2C21 and 3A12) in dog liver microsomes by enzyme-linked immunosorbent assay. Xenobiotica 26:755-763.
7. Fink-Gremmels J (2008) Implications of hepatic cytochrome P450-related biotransformation processes in veterinary sciences. Eur J Pharmacol 585:502-509.
8. Lu P, Singh SB, Carr BA, Fang Y, Xiang CD, Rushmore TH, Rodrigues AD, and Shou M (2005) Selective inhibition of dog hepatic CYP2B11 and CYP3A12. J Pharmacol Exp Ther 313:518-528.
9. McGinnity DF, Waters NJ, Tucker J, and Riley RJ (2008) Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactions. Drug Metab Dispos 36:1126-1134.
10. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J Biol Chem 239:2379-2385.
11. Parikh A, Gillam EM, and Guengerich FP (1997) Drug metabolism by Escherichia coli expressing human cytochromes P450. Nat Biotechnol 15:784-788.
12. Petkewich R (2007) Big pharma chases dogs and cats. Chem Eng News 85:31-34.
13. Pritchard MP, Glancey MJ, Blake JA, Gilham DE, Burchell B, Wolf CR, and Friedberg T (1998) Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli. Pharmacogenetics 8:33-42.
14. Proctor NJ, Tucker GT, and Rostami-Hodjegan A (2004) Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 34:151-178.
15. Shen AL, Porter TD, Wilson TE, and Kasper CB (1989) Structural analysis of the FMN binding domain of NADPH-cytochrome P-450 oxidoreductase by site-directed mutagenesis. J Biol Chem 264:7584-7589.
16. Shou M, Norcross R, Sandig G, Lu P, Li Y, Lin Y, Mei Q, Rodrigues AD, and Rushmore TH (2003) Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes P450. Drug Metab Dispos 31:1161-1169.
17. Strobel HW and Dignam JD (1978) Purification and properties of NADPH-cytochrome P-450 reductase. Methods Enzymol 52:89-96.
18. Tibbitts J (2003) Issues related to the use of canines in toxicologic pathology-issues with pharmacokinetics and metabolism. Toxicol Pathol 31(Suppl):17-24.
19. Turpeinen M, Ghiciuc C, Opritoui M, Tursas L, Pelkonen O, and Pasanen M (2007) Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: a comparative study in vitro. Xenobiotica 37:1367-1377.
20. Uchida T, Komori M, Kitada M, and Kamataki T (1990) Isolation of cDNAs coding for three different forms of liver microsomal cytochrome P-450 from polychlorinated biphenyl-treated beagle dogs. Mol Pharmacol 38:644-651.
21. Venkatakrishnan K, von Moltke LL, and Greenblatt DJ (2001) Application of the relative activity factor approach in scaling from heterologously expressed cytochromes P450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther 297:326-337.
22. Zhang H, Davis CD, Sinz MW, and Rodrigues AD (2007) Cytochrome P450 reactionphenotyping: an industrial perspective. Expert Opin Drug Metab Toxicol 3:667-687.